TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma

References

• Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749.
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–511.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Sirivatanauksorn Y, Sirivatanauksorn V, Bhattacharya S, et al. Genomic heterogeneity in synchronous hepatocellular carcinomas. Gut. 1999;45(5):761–765.
   PubMed Web of Science ®Google Scholar
• Lin DC, Mayakonda A, Dinh HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017;77(9):2255–2265.
   PubMed Web of Science ®Google Scholar
• Xue R, Li R, Guo H, et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):998–1008.
   PubMed Web of Science ®Google Scholar
• Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014;60(6):1983–1992.
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.
   PubMed Web of Science ®Google Scholar
• Chen YL, Jeng YM, Chang CN, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg. 2014;12(7):659–665.
   PubMed Web of Science ®Google Scholar
• Lee HW, Park TI, Jang SY, et al. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma. Medicine (Baltimore). 2017;96(5):e5766.
   PubMedGoogle Scholar
• Li X, Xu W, Kang W, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics. 2018;8(6):1740–1751.
   PubMed Web of Science ®Google Scholar
• Liao W, Yang H, Xu H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget. 2016;7(26):40481–40490.
   PubMed Web of Science ®Google Scholar
• Jiao J, Watt GP, Stevenson HL, et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors. Hepatol Commun. 2018;2(6):718–731.
   PubMed Web of Science ®Google Scholar
• Dansk Selskab for Gastroenterologi og Hepatology. Hepatocellulaert Carcinom. [Published 2015; Oct 2020]. Available from: https://www.dsgh.dk/index.php/lever/hcc
   Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Milbury CA, Zhong Q, Lin J, et al. Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomol Detect Quantif. 2014;1(1):8–22.
   PubMedGoogle Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support . J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
   PubMed Web of Science ®Google Scholar
• Madsen AT, Winther-Larsen A, McCulloch T, et al. Genomic profiling of circulating tumor DNA predicts outcome and demonstrates tumor evolution in ALK-positive non-small cell lung cancer patients. Cancers (Basel). 2020;12(4):947.
   PubMed Web of Science ®Google Scholar
• Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40(1):9–14.
   PubMed Web of Science ®Google Scholar
• Sarah Paisley BI, Aurélie B, Albuquerque M, et al. TERT promoter mutations and liver carcinogenesis: identification and quantification of mutation status by digital PCR analysis on formol-fixed paraffin-embedded samples. [Published 2020]. https://ilc-congress.eu/digital-ilc-2020-abstract-book/
   Google Scholar
• Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014;120(24):3896–3901.
   PubMed Web of Science ®Google Scholar
• Scholer LV, Reinert T, Orntoft MW, et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res. 2017;23(18):5437–5445.
   PubMed Web of Science ®Google Scholar
• Fittall MW, Van Loo P. Translating insights into tumor evolution to clinical practice: promises and challenges. Genome Med. 2019;11(1):20.
   PubMed Web of Science ®Google Scholar
• Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–313.
   PubMed Web of Science ®Google Scholar
• Aravindan N, Aravindan S, Herman TS, et al. EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma. Radiat Res. 2013;179(3):304–312.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Nakajima A, Sashida G, et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res. 2002;8(11):3341–3347.
   PubMed Web of Science ®Google Scholar
• Shapira S, Granot G, Mor-Tzuntz R, et al. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer Lett. 2012;323(2):223–231.
   PubMed Web of Science ®Google Scholar